MarketBeat
12 Aug 2026, 15:05 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
Commercial insurance coverage for CARDAMYST increased from 25% at June 30 to approximately 50% of commercially insured lives shortly after. — Significant expansion in payer access is a primary driver for prescription volume growth and higher revenue per prescription.
+0.60Milestone has activated lead clinical sites for its pivotal Phase III ReVeRA-301 trial for AFib-RVR, targeting a market of 3-4 million potential US patients. — Successful label expansion into a much larger patient population represents a significant long-term valuation catalyst.
+0.50CARDAMYST saw a strong uptick in early adoption, with total prescriptions growing from 300 in Q1 to over 1,200 in Q2. — Positive early commercial traction validates the product's market fit and physician acceptance.
+0.40Continue reading
6 related stories
Search tags
Management noted that many current prescribers have been one-time writers, though they have only reached half of their high-value physician targets. — Low prescription frequency per doctor suggests a challenge in establishing habitual use or a high churn of early trialers.
-0.20The company reported second-quarter product revenue of $0.6 million. — While it establishes a revenue baseline, the absolute figure is currently immaterial to the company's overall valuation.
+0.10Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
5h ago
